Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth.

In this podcast, Motley Fool co-founder David Gardner highlights 10 standout Motley Fool Rule Breakers episodes from this ...

EPR Properties' aggressive theater divestitures and reinvestment in experiential assets have driven 6.1% AFFO per share ...

More than six years later, that has yet to be accomplished and investors have shown their displeasure, with the stock up just about 7% over the past five years. You can do way better than Truist. Buy ...